Cel­gene's Michael Pehl leaps up to lead role at Im­munomedics; GSK nabs Hal Bar­ron to helm R&D; Aim­mune CEO to step down

→ Michael Pehl will take the top job at Im­munomedics next month af­ter 11 years at Cel­gene, where he was most re­cent­ly head of hema­tol­ogy and on­col­o­gy. As pres­i­dent and CEO, his pri­or­i­ty will be push­ing for the ap­proval and mar­ket­ing of an­ti­body-drug con­ju­gate IM­MU-132. On his side will be fel­low Cel­gene vet Bren­dan De­laney, who has been named chief com­mer­cial of­fi­cer.

→ Por­to­la Phar­ma­ceu­ti­cals has brought on John (Jack) Lawrence, pre­vi­ous­ly VP and head of car­dio­vas­cu­lar at Bris­tol-My­ers Squibb, as CMO. “Jack’s rep­u­ta­tion and achieve­ments in glob­al throm­bo­sis prod­uct de­vel­op­ment and reg­u­la­to­ry ap­provals will be valu­able as­sets to Por­to­la as we be­gin to launch be­trix­a­ban and pre­pare for the po­ten­tial ap­proval of an­dex­anet in 2018,” said com­pa­ny $PT­LA CEO William Lis in a state­ment. “We’re pleased to add his ex­ec­u­tive lead­er­ship and ex­per­tise to our man­age­ment team to help us con­tin­ue to ad­vance Por­to­la as a lead­ing throm­bo­sis and hema­to­log­ic biotech­nol­o­gy com­pa­ny.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER